Allarity Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
ALLR$0.91-3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| 2025 | 2024 | |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(11,231) | $(24,515) |
| Reconciliation of net loss to net cash used in operating activities: | ||
| Depreciation and amortization | (13) | 9 |
| Intangible asset impairment | — | 9,703 |
| Common stock issued for services | 200 | 336 |
| Stock-based compensation expense | 482 | 71 |
| Unrealized foreign exchange gain | 1,238 | (126) |
| Non-cash interest expense | 185 | 230 |
| Change in fair value of warrant derivative liabilities | (1) | (2,677) |
| Deferred income taxes | — | (446) |
| Changes in operating assets and liabilities: | ||
| Other current assets | (150) | 94 |
| Unearned revenue | — | 207 |
| Tax credit receivable | (96) | 45 |
| Prepaid expenses | (1,603) | 274 |
| Accounts payable | (1,139) | (4,108) |
| Accrued liabilities | (2,699) | 3,536 |
| Income taxes payable | 7 | 15 |
| Net cash used in operating activities | (14,820) | (17,352) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchase of property and equipment | (8) | (298) |
| Net cash used in investing activities | (8) | (298) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from 3i promissory notes | — | 1,340 |
| Repayment of 3i debt | — | (1,340) |
| Proceeds from ATM sales of common stock, net of issuance costs | 11,143 | 37,354 |
| Net proceeds from common stock and pre-funded warrant issuance | 2,695 | — |
| Proceeds from issuance of Convertible Redeemable Series A Preferred Stock | — | 2,938 |
| Redemption of Convertible Redeemable Series A Preferred Stock | — | (3,500) |
| Common stock repurchase | (3,190) | — |
| Net cash provided by financing activities | 10,648 | 36,792 |
| Net increase (decrease) in cash | (4,180) | 19,142 |
| Effect of exchange rate changes on cash | (667) | 225 |
| Cash, beginning of year | 19,533 | 166 |
| Cash, end of year | $14,687 | $19,533 |
(in thousands)
| 2025 | 2024 | |
|---|---|---|
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $— | $423 |
| Cash received for interest | $801 | $503 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Stock issued in conjunction with consulting agreement | $200 | $90 |
| Issuance of common shares on conversion of 3i Exchange Warrants | $— | $405 |
| Conversion of Series A Redeemable Preferred Stock to common stock | $— | $1,819 |
| Deemed dividends on Series A Preferred Stock | $— | $299 |
| Gain on extinguishment of Series A Preferred Stock | $— | $222 |
| Deemed dividend on Convertible Redeemable Series A Preferred Stock | $— | $562 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.